Drugs / REDAFAMDASTAT
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT01092845 | Apr → Jun 2010 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT01002625 | Nov 2009 → Jan 2010 | — | Pfizer | Terminated | No outcome recorded |
| Phase 1 | NCT00918164 | May → Jul 2009 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00836082 | Feb → Jul 2009 | chronic pain syndrome | Pfizer | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT02216097 | Oct 2014 → Mar 2015 | post-traumatic stress disorder | Pfizer | Terminated | No outcome recorded |
| Phase 2 | NCT00981357 | Nov 2009 → May 2010 | osteoarthritis, knee | Pfizer | Completed | No outcome recorded |
Also used as a comparator or background therapy in 4 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT01665573 Comparator | Jul 2012 → Oct 2015 | — | Yale University | Completed | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT02134080 Comparator | May 2014 → Mar 2017 | Tourette syndrome | Yale University | Terminated | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT03386487 Comparator | Jan 2019 → Jul 2022 | cannabis dependence | Yale University | Completed | No outcome recorded |
| Phase 2 | NCT01618656 Comparator | Sep 2012 → Mar 2016 | cannabis dependence | Yale University | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | REDAFAMDASTAT | ChEMBL registry synonym — accepted as the source's own label CHEMBL1651534 ↗ |
| Known as | CPD 23 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1651534 ↗ |
| Known as | PF-04457845 | “The efficacy, safety and tolerability of the FAAH Inhibitor PF-0447845 in reducing cannabis use will be studied in a 4-site randomized, double-blind, placebo-controlled,...” NCT03386487 ↗ |
| Known as | PF-4457845 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1651534 ↗ |
| Action | Inhibit | “FAAH inhibitor” NCT00836082 ↗ |
| Modality | Small molecule | — CHEMBL1651534 ↗ |
| Route | Oral | “Oral solution of 0.5mg given once daily for 14 days.” NCT00836082 ↗ |
| Target | FAAH | “PF-04457845 has been shown to inactivate the FAAH enzyme in animals and healthy human volunteers.” NCT00981357 ↗ |